Dr. Lauren Kim speaks with Adarsh Mallepady and Dr. Cory Trankle about their large-scale retrospective study of nearly 4 million patients examining the risk of nephrogenic systemic fibrosis after gadolinium-based contrast administration in those with advanced renal dysfunction. They discuss how modern group 2 and macrocyclic agents were associated with an exceedingly low incidence of NSF, offering important reassurance for evidence-based contrast use and evolving clinical practice.